Adjuvant Sorafenib Does Not Improve Survival in Renal Cell Carcinoma
Active surveillance remains the standard of care for patients at intermediate or high risk of recurrence following nephrectomy.
Bryant Furlow
Contributing Writer
Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a BS in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research and health care policy. Prior to joining Haymarket in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.
